Advisors Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $61.3M | Buy |
1,010,102
+75,107
| +8% | +$4.38M | 0.71% | 43 |
|
|
2025
Q4 | $50.4M | Buy |
934,995
+21,015
| +2% | +$1.01M | 0.59% | 49 |
|
|
2025
Q3 | $41.2M | Buy |
913,980
+41,867
| +5% | +$1.96M | 0.51% | 56 |
|
|
2025
Q2 | $40.4M | Buy |
872,113
+59,276
| +7% | +$2.91M | 0.55% | 54 |
|
|
2025
Q1 | $49.6M | Buy |
812,837
+33,874
| +4% | +$1.97M | 0.77% | 39 |
|
|
2024
Q4 | $44.1M | Buy |
778,963
+83,786
| +12% | +$4.68M | 0.69% | 39 |
|
|
2024
Q3 | $36M | Buy |
695,177
+520,498
| +298% | +$24.4M | 0.59% | 52 |
|
|
2024
Q2 | $7.25M | Buy |
174,679
+11,210
| +7% | +$502K | 0.13% | 161 |
|
|
2024
Q1 | $8.87M | Buy |
163,469
+25,768
| +19% | +$1.31M | 0.16% | 145 |
|
|
2023
Q4 | $7.07M | Sell |
137,701
-3,649
| -3% | -$192K | 0.14% | 148 |
|
|
2023
Q3 | $8.2M | Buy |
141,350
+6,024
| +4% | +$369K | 0.21% | 123 |
|
|
2023
Q2 | $8.65M | Sell |
135,326
-60,968
| -31% | -$4.09M | 0.21% | 127 |
|
|
2023
Q1 | $13.6M | Buy |
196,294
+11,253
| +6% | +$794K | 0.35% | 96 |
|
|
2022
Q4 | $13.3M | Buy |
185,041
+2,320
| +1% | +$175K | 0.36% | 88 |
|
|
2022
Q3 | $14M | Buy |
182,721
+16,327
| +10% | +$1.18M | 0.37% | 90 |
|
|
2022
Q2 | $12.8M | Buy |
166,394
+4,328
| +3% | +$330K | 0.39% | 80 |
|
|
2022
Q1 | $11.8M | Sell |
162,066
-3,836
| -2% | -$258K | 0.32% | 95 |
|
|
2021
Q4 | $10.3M | Buy |
165,902
+6,685
| +4% | +$392K | 0.28% | 101 |
|
|
2021
Q3 | $9.42M | Buy |
159,217
+1,578
| +1% | +$104K | 0.29% | 106 |
|
|
2021
Q2 | $10.5M | Sell |
157,639
-201,995
| -56% | -$13.2M | 0.33% | 97 |
|
|
2021
Q1 | $22.7M | Buy |
359,634
+7,499
| +2% | +$467K | 0.8% | 39 |
|
|
2020
Q4 | $21.8M | Sell |
352,135
-52,483
| -13% | -$3.23M | 0.84% | 38 |
|
|
2020
Q3 | $24.4M | Sell |
404,618
-29,165
| -7% | -$1.76M | 1.14% | 24 |
|
|
2020
Q2 | $25.5M | Sell |
433,783
-75,333
| -15% | -$4.51M | 1.26% | 19 |
|
|
2020
Q1 | $28.4M | Buy |
509,116
+11,245
| +2% | +$687K | 1.8% | 6 |
|
|
2019
Q4 | $32M | Buy |
497,871
+22,836
| +5% | +$1.31M | 1.49% | 10 |
|
|
2019
Q3 | $24.1M | Buy |
475,035
+43,180
| +10% | +$2.03M | 1.31% | 14 |
|
|
2019
Q2 | $19.6M | Buy |
431,855
+29,181
| +7% | +$1.36M | 1.16% | 18 |
|
|
2019
Q1 | $19M | Buy |
402,674
+161,585
| +67% | +$8.05M | 1.18% | 15 |
|
|
2018
Q4 | $12.5M | Sell |
241,089
-5,253
| -2% | -$282K | 0.91% | 39 |
|
|
2018
Q3 | $15.3M | Sell |
246,342
-10,217
| -4% | -$606K | 1% | 31 |
|
|
2018
Q2 | $14.2M | Buy |
+256,559
| New | +$13.9M | 0.98% | 40 |
|
Other funds holding BMY
VCM
VPM
Advisors Capital Management's BMY Position: Q1 2026 in Review
Advisors Capital Management increased its Bristol-Myers Squibb (BMY) stake by 8% in Q1 2026, buying an estimated $4.38M and bringing the position to 1,010,102 shares worth $61.3M. The position accounts for 0.71% of the portfolio, ranked #43.
Advisors Capital Management first reported a position in BMY in Q2 2018 and has held it in 32 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Advisors Capital Management held 1,010,102 shares of Bristol-Myers Squibb worth $61.3M as of Q1 2026.
- Advisors Capital Management bought 75,107 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.38M.
- Bristol-Myers Squibb made up 0.71% of Advisors Capital Management's portfolio in Q1 2026, its #43 holding.
- Advisors Capital Management first reported a position in Bristol-Myers Squibb in Q2 2018 and has held it in 32 quarters since.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Advisors Capital Management's 13F filing for Q1 2026, filed 1 May 2026.